In yesterday’s Wall Street session, OpGen Inc. (NASDAQ:OPGN) shares traded at $1.18, up 19.17% from the previous session.
As of this writing, 1 analysts cover OpGen Inc. (NASDAQ:OPGN). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $3.20 and a low of $3.20, we find $3.20. Given the previous closing price of $0.99, this indicates a potential upside of 223.23 percent. OPGN stock price is now -36.76% away from the 50-day moving average and -81.14% away from the 200-day moving average. The market capitalization of the company currently stands at $6.43M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $3.20 as their price target over the next twelve months.
With the price target of $2.30, Alliance Global Partners recently initiated with Buy rating for OpGen Inc. (NASDAQ: OPGN). On February 07, 2018, H.C. Wainwright reiterated its ‘Buy’ rating on the stock by increasing its target price from $1 to quote $9, while ‘Rodman & Renshaw’ rates the stock as ‘Buy’.
A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OPGN stock. A new stake in OpGen Inc. shares was purchased by FNY INVESTMENT ADVISERS, LLC during the first quarter worth $97,000. HRT FINANCIAL LP invested $11,000 in shares of OPGN during the first quarter. In the first quarter, ERGOTELES LLC acquired a new stake in OpGen Inc. valued at approximately $8,000. GOLDMAN SACHS GROUP INC acquired a new stake in OPGN for approximately $1,000. TWO SIGMA SECURITIES, LLC purchased a new stake in OPGN valued at around $1,000 in the second quarter. In total, there are 23 active investors with 16.40% ownership of the company’s stock.
Thursday morning saw OpGen Inc. (NASDAQ: OPGN) opened at $0.9900. During the past 12 months, OpGen Inc. has had a low of $0.93 and a high of $18.40. As of last week, the company has a debt-to-equity ratio of 0.89, a current ratio of 1.10, and a quick ratio of 1.10. The fifty day moving average price for OPGN is $1.8660 and a two-hundred day moving average price translates $6.2556 for the stock.
The latest earnings results from OpGen Inc. (NASDAQ: OPGN) was released for Sep, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$6, missing analysts’ expectations of -$2.4 by -3.6. This compares to -$3.17 EPS in the same period last year. The company reported revenue of $0.45 million for the quarter, compared to $1.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -63.76 percent. For the current quarter, analysts expect OPGN to generate $600k in revenue.
OpGen Inc.(OPGN) Company Profile
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company’s products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
